本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Landos Biopharma, Inc.

22.93
+0.0000
成交量:- -
成交额:- -
市值:7,167.55万
市盈率:-5.74
高:22.93
开:22.93
低:22.93
收:22.93
数据加载中...
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/23

交易所摘牌声明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/16

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/04/10

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/10

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/25

重要事件披露

Form 8-K - Current report
2024/03/21

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/21

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/21

重要事件披露

Form 8-K - Current report
2024/02/15

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/04

重要事件披露

Form 8-K - Current report
2023/11/21

重要事件披露

Form 8-K - Current report
2023/11/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09

重要事件披露

Form 8-K - Current report